Literature DB >> 18798273

Bone marrow stroma cells regulate TIEG1 expression in acute lymphoblastic leukemia cells: role of TGFbeta/BMP-6 and TIEG1 in chemotherapy escape.

Guri Døsen-Dahl1, Else Munthe, Marit Kveine Nygren, Heidi Stubberud, Marit E Hystad, Edith Rian.   

Abstract

The bone marrow microenvironment regulates early B lymphopoiesis and protects leukemia cells against chemotherapy treatment, thus the microenvironment may serve as a sanctuary site for these cells. Yet, few factors that contribute to this process are known. We have explored the role of transforming growth factor beta (TGFbeta) and bone morphogenetic protein-6 (BMP-6) and one target gene, TGFbeta inducible early gene 1 (TIEG1), in the communication between stroma cells and acute lymphoblastic leukemia (ALL) cell lines and their escape from chemotherapy. Here, we have demonstrated TIEG1 expression in both normal B progenitor cells and ALL cells, which increased rapidly upon TGFbeta and BMP-6 treatment. Stimulation with TGFbeta or BMP-6, as well as overexpression of TIEG1 inhibited proliferation. Furthermore, interaction with stroma cells induced TIEG1 expression in ALL cells, inhibited their proliferation and protected the cells against chemotherapeutic treatment. Similarly, treatment with TGFbeta or BMP-6, as well as overexpression of TIEG1, protected ALL cells against chemotherapy-induced cell death. These data suggest that TGFbeta and BMP-6 in the bone marrow microenvironment allow leukemia cells to escape therapy. Further, the data indicate that TIEG1 might be involved in mediating this effect from the microenvironment onto the leukemia cells. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18798273     DOI: 10.1002/ijc.23833

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  9 in total

1.  Generation and characterization of an immortalized human mesenchymal stromal cell line.

Authors:  Magne Skårn; Paul Noordhuis; Meng-Yu Wang; Marjan Veuger; Stine Henrichson Kresse; Eivind Valen Egeland; Francesca Micci; Heidi Maria Namløs; Anne-Mari Håkelien; Solveig Mjelstad Olafsrud; Susanne Lorenz; Guttorm Haraldsen; Gunnar Kvalheim; Leonardo Andrés Meza-Zepeda; Ola Myklebost
Journal:  Stem Cells Dev       Date:  2014-06-30       Impact factor: 3.272

Review 2.  Mammalian Krüppel-like factors in health and diseases.

Authors:  Beth B McConnell; Vincent W Yang
Journal:  Physiol Rev       Date:  2010-10       Impact factor: 37.312

3.  Hydroxyurea responsiveness in β-thalassemic patients is determined by the stress response adaptation of erythroid progenitors and their differentiation propensity.

Authors:  Farzin Pourfarzad; Marieke von Lindern; Azita Azarkeivan; Jun Hou; Sima Kheradmand Kia; Fatemehsadat Esteghamat; Wilfred van Ijcken; Sjaak Philipsen; Hossein Najmabadi; Frank Grosveld
Journal:  Haematologica       Date:  2012-10-25       Impact factor: 9.941

Review 4.  Contribution of bone microenvironment to leukemogenesis and leukemia progression.

Authors:  F Ayala; R Dewar; M Kieran; R Kalluri
Journal:  Leukemia       Date:  2009-09-03       Impact factor: 11.528

5.  Cancer Tissue Engineering: A Novel 3D Polystyrene Scaffold for In Vitro Isolation and Amplification of Lymphoma Cancer Cells from Heterogeneous Cell Mixtures.

Authors:  Carlos E Caicedo-Carvajal; Qing Liu; Yvonne Remache; Andre Goy; K Stephen Suh
Journal:  J Tissue Eng       Date:  2011-09-05       Impact factor: 7.813

6.  Mesenchymal stromal cells derived from the bone marrow of acute lymphoblastic leukemia patients show altered BMP4 production: correlations with the course of disease.

Authors:  Ángeles Vicente López; Miriam Nohemí Vázquez García; Gustavo J Melen; Ana Entrena Martínez; Isabel Cubillo Moreno; Javier García-Castro; Manuel Ramírez Orellana; Agustín Gregorio Zapata González
Journal:  PLoS One       Date:  2014-01-06       Impact factor: 3.240

7.  Bone marrow stroma-derived PGE2 protects BCP-ALL cells from DNA damage-induced p53 accumulation and cell death.

Authors:  Elin Hallan Naderi; Seham Skah; Hege Ugland; Ola Myklebost; Dagny Lise Sandnes; Maria Lyngaas Torgersen; Dag Josefsen; Ellen Ruud; Soheil Naderi; Heidi Kiil Blomhoff
Journal:  Mol Cancer       Date:  2015-01-27       Impact factor: 27.401

8.  Discovery of novel candidates for anti-liposarcoma therapies by medium-scale high-throughput drug screening.

Authors:  Iwona Grad; Robert Hanes; Pilar Ayuda-Durán; Marieke Lydia Kuijjer; Jorrit M Enserink; Leonardo A Meza-Zepeda; Ola Myklebost
Journal:  PLoS One       Date:  2021-03-10       Impact factor: 3.752

9.  Rationale and efficacy of proteasome inhibitor combined with arsenic trioxide in the treatment of acute promyelocytic leukemia.

Authors:  S Ganesan; A A Alex; E Chendamarai; N Balasundaram; H K Palani; S David; U Kulkarni; M Aiyaz; R Mugasimangalam; A Korula; A Abraham; A Srivastava; R A Padua; C Chomienne; B George; P Balasubramanian; V Mathews
Journal:  Leukemia       Date:  2016-08-18       Impact factor: 11.528

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.